348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)

Background

To investigate the clinical significance of urine protein quantitative test UPCR (ratio of urinary protein amount measured and creatinine concentration in urine) when anti-angiogenesis inhibitors are used.

Methods

From January 2018 to December 2018, a survey was conducted based on the medical records of gastric cancer and colorectal cancer cases with urine protein qualitative value test (QV) of 2+ or higher during the use of anti-angiogenesis inhibitors at 9 institutions participating in Onconephrology Consortium. The primary endpoint was the ratio of UPCR worst value less than 2 (Low UPCR) in QV 2+ cases. The secondary endpoints were comparison of Low UPCR and UPCR worst value2 or higher (High UPCR), the use status of angiogenesis inhibitors, changes in urine protein test values (qualitative/quantitative), subsequent treatment information, and patient background factors and other relationships.

Results

Among 71 cases enrolled, the proportion of Low UPCR in QV 2+ cases (n=53) was 66% (n=35). In a comparison between Low (n=36) and High UPCR cases (n=24), High UPCR tended to occur in cases of heavy body weight, and its cut-off value was 52.45 kg (OR 4.25, 95%CI 1.30-13.86, p=0.017). A significant correlation was also observed between UPCR levels and the single dose of bevacizumab (p=0.033) or ramcirumab (p=0.018).

Conclusions

The relationship between UPCR levels and body weight or single dose was shown, but there is a possibility that physical disparity and the amount of creatinine excretion may have an effect.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M. Nakamura: Honoraria (self): Daiichi Sankyo; Honoraria (self): Lilly; Honoraria (self): Chugai; Honoraria (self): Mochida; Honoraria (self): Bristol Myers Squibb; Honoraria (self): Taiho. T. Funakoshi: Research grant/Funding (institution), TF belongs to an endowed department sponsored partly by Chugai Pharmaceutical Co., Ltd.: Chugai. E. Baba: Honoraria (self): Lilly; Research grant/Funding (institution): Taiho; Research grant/Funding (institution): Chugai. Y. Mihara: Honoraria (self): Chugai. M. Muto: Honoraria (self), Research grant/Funding (institution), MM belongs to an endowed department sponsored partly by Chugai Pharmaceutical Co., Ltd.: Chugai; Research grant/Funding (self): Sanofi. M. Yanagita: Honoraria (self): Chugai; Honoraria (self): Kyowa Hakko Kirin; Research grant/Funding (institution): Kyowa Hakko Kirin; Research grant/Funding (institution): Tanabe Mitsubishi; Research grant/Funding (institution): Nippon Boehringer Ingelheim; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Baxter; Research grant/Funding (institution): Chugai; Research grant/Funding (institution): Kyowa Hakko Kirin; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): Takeda. All other authors have declared no conflicts of interest.